Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17934406 | 0.86 | EGFR (0.58) | EGFRKDR | |
| SCHEMBL17934387 | 0.85 | EGFR (0.59) | EGFRKDR | |
| SCHEMBL17934351 | 0.83 | EGFR (0.60) | EGFRKDR | |
| SCHEMBL21750829 | 0.82 | EGFR (0.45) | EGFRKDR | |
| SCHEMBL21750963 | 0.82 | EGFR (0.48) | EGFRKDR | |
| SCHEMBL21750828 | 0.82 | EGFR (0.54) | EGFRKDR | |
| SCHEMBL17934393 | 0.81 | EGFR (0.55) | EGFRKDR | |
| SCHEMBL17934408 | 0.81 | EGFR (0.57) | EGFRKDR | |
| SCHEMBL21751018 | 0.81 | EGFR (0.53) | EGFRKDR | |
| SCHEMBL21750943 | 0.81 | EGFR (0.48) | EGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246328-B1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2020-07-22 | — | — | EP | disclosed |
| EP-3246328-B1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2020-07-22 | — | — | EP | disclosed |
| US-10106508-B2 | Quinazoline heterocyclic compound as EGFR kinase inhibitor and preparation and application thereof | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2018-10-23 | — | — | US | disclosed |
| US-20170355683-A1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR AND PREPARATION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2017-12-14 | — | — | US | disclosed |
| US-20170355683-A1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR AND PREPARATION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2017-12-14 | — | — | US | disclosed |
| US-20170355683-A1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR AND PREPARATION AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2017-12-14 | — | — | US | disclosed |
| EP-3246328-A1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246328-A1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2017-11-22 | — | — | EP | disclosed |
| WO-2016112847-A1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2016-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355683-A1 | QUINAZOLINE HETEROCYCLIC COMPOUND AS EGFR KINASE INHIBITOR AND PREPARATION AND APPLICATION THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDR 85/4885 |
| US-10106508-B2 | Quinazoline heterocyclic compound as EGFR kinase inhibitor and preparation and application thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885KDR 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.